Abstract
Locally advanced breast cancer (LABC) continues to be a common presentation of breast cancer worldwide. Various serum markers have been studied to know the behaviour, metastasis and prognosis of breast cancer without going through any invasive procedure. CA 15-3 measures the protein product of the MUC 1 gene and is the most commonly used serum marker in breast cancer. The main use of serum CA 15-3 is monitoring therapy response and elevated levels are associated with metastatic disease and in non-metastatic patients, it is associated with poor prognosis. The aim of the study was to know the role of serum CA 15-3 level in diagnosis, prognosis and therapy response in patients with locally advanced breast cancer and to assess its relationship with other variables like tumor size, microscopic grade, nodal burden and Ki-67 antigen expression. Serum CA 15-3 levels significantly decreased after neo-adjuvant chemotherapy and mastectomy and it remained elevated in patients with suspected or hidden metastasis. Serum CA 15-3 levels exhibited positive statistically significant correlation with tumor size. DOI: 10.21276/AWCH.1782
Highlights
Advanced breast cancer (LABC) continues to be a common presentation of breast cancer worldwide
The main use of serum CA 15-3 is monitoring therapy response and elevated levels are associated with metastatic disease and in non-metastatic patients, it is associated with poor prognosis.[5]
The aim of the study was to know the role of serum CA 15-3 level in diagnosis, prognosis and therapy response in patients with locally advanced breast cancer and to assess its relationship with other variables like tumor size, microscopic grade, nodal burden and Ki-67 antigen expression
Summary
Advanced breast cancer (LABC) continues to be a common presentation of breast cancer worldwide. Patients with subset of stage IIB (T3N0) and III of the TNM classification are included in LABC. In this classification system, patients are included if they have tumor greater than 5 cm or that involve the skin and chest wall. Advanced disease includes patients with fixed axillary lymph nodes or ipsilateral supraclavicular, infraclavicular or internal mammary nodal involvement. Inflammatory breast carcinoma (IBC) is included in this category.[1] Multidisciplinary therapy has become the treatment of choice for these patients.[2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
